BTIG Research Reaffirms Buy Rating for Perspective Therapeutics (NASDAQ:CATX)

Perspective Therapeutics (NASDAQ:CATX)‘s stock had its “buy” rating reaffirmed by BTIG Research in a report issued on Tuesday,Benzinga reports. They presently have a $14.00 price target on the stock. BTIG Research’s target price indicates a potential upside of 480.91% from the stock’s current price.

Several other analysts have also weighed in on the company. UBS Group lowered their price objective on Perspective Therapeutics from $18.00 to $7.00 and set a “buy” rating for the company in a report on Friday, November 21st. Truist Financial began coverage on Perspective Therapeutics in a research report on Monday, November 24th. They issued a “buy” rating and a $12.00 target price for the company. Finally, B. Riley dropped their price target on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Perspective Therapeutics has an average rating of “Buy” and a consensus target price of $11.00.

Perspective Therapeutics Stock Down 15.1%

CATX opened at $2.41 on Tuesday. The stock has a market capitalization of $179.15 million, a PE ratio of -2.68 and a beta of 1.18. Perspective Therapeutics has a 1-year low of $1.60 and a 1-year high of $5.39.

About Perspective Therapeutics

Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities.